Cascadian Therapeutics Added to the Nasdaq Biotechnology Index
13 Dezembro 2017 - 11:35AM
Cascadian Therapeutics, Inc. (Nasdaq:CASC), a clinical-stage
biopharmaceutical company, today announced that it has been
selected for addition to the Nasdaq Biotechnology Index®
(Nasdaq:NBI), which will become effective prior to U.S. market open
on Monday, December 18, 2017.
The Nasdaq Biotechnology Index is designed to track the
performance of a set of securities listed on the Nasdaq Stock
Market® (Nasdaq®) that are classified as either biotechnology or
pharmaceutical according to the Industry Classification Benchmark
(ICB). The Nasdaq Biotechnology Index is re-ranked annually and all
securities in the index are listed on the Nasdaq Global Market or
the Nasdaq Global Select Market, and meet minimum market value and
share volume requirements among other criteria. For more
information about the Nasdaq Biotechnology Index, including
eligibility criteria, visit www.nasdaq.com.
About Cascadian Therapeutics
Cascadian Therapeutics is a clinical-stage biopharmaceutical
company dedicated to developing innovative product candidates for
the treatment of cancer. Its lead product candidate, tucatinib, is
an investigational oral, selective small molecule HER2 inhibitor.
Cascadian Therapeutics is conducting a randomized, double-blind,
controlled pivotal clinical trial called HER2CLIMB, which is
comparing tucatinib vs. placebo, each in combination with
capecitabine and trastuzumab, in patients with locally advanced or
metastatic HER2+ breast cancer with and without brain metastases,
who have previously been treated with trastuzumab, pertuzumab and
T-DM1. Additional details on HER2CLIMB can be found at
www.HER2CLIMB.com or www.clinicaltrials.gov. Tucatinib is also
being studied in other cancers through investigator initiated
studies, including HER2+ metastatic colorectal cancer and earlier
lines of HR+/HER2+ metastatic breast cancer. For more information,
please visit www.cascadianrx.com.
Source: Cascadian Therapeutics, Inc.
Contact:Cascadian TherapeuticsMonique
Greer206-801-2107mgreer@cascadianrx.com
Cascadian Therapeutics, Inc. (NASDAQ:CASC)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Cascadian Therapeutics, Inc. (NASDAQ:CASC)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024
Notícias em tempo-real sobre Cascadian Therapeutics, Inc. (delisted) da NASDAQ bolsa de valores: 0 artigos recentes
Mais Notícias de